Puma Biotechnology (NASDAQ:PBYI) Insider Sells $29,482.32 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Douglas Hunt sold 5,014 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $29,482.32. Following the completion of the transaction, the insider directly owned 155,907 shares of the company’s stock, valued at approximately $916,733.16. This represents a 3.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Puma Biotechnology Stock Performance

Shares of NASDAQ PBYI opened at $6.11 on Friday. The firm has a market cap of $307.88 million, a P/E ratio of 8.26 and a beta of 1.19. Puma Biotechnology, Inc. has a 1 year low of $2.58 and a 1 year high of $6.29. The firm’s 50 day moving average price is $5.44 and its 200 day moving average price is $4.80.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.12. Puma Biotechnology had a return on equity of 36.17% and a net margin of 17.45%.The company had revenue of $54.48 million for the quarter, compared to analyst estimates of $51.00 million. As a group, equities analysts predict that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Puma Biotechnology News Roundup

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: PBYI has moved above its 200‑day moving average — a technical breakout that can attract momentum and trend‑following buyers and provide some support to the share price. Read More.
• Neutral Sentiment: The company disclosed inducement equity awards granted to December 2025 new hires under Nasdaq Listing Rule 5635(c)(4). These are routine hiring grants that can cause modest dilution over time but are typically not material to near‑term trading. Read More.
• Negative Sentiment: Insider selling by senior management is the clearest negative catalyst: CEO Alan H. Auerbach sold roughly 34,950 shares across Jan. 6–7 at about $5.84–$5.88, and director Douglas M. Hunt sold about 8,987 shares over the same dates at similar prices. While insiders retain large holdings, these sales can be read by the market as reduced near‑term insider conviction or simply personal liquidity events — either way they often pressure sentiment. SEC filings for the transactions are posted here: Read More. and Read More.. Additional trade notices: Read More.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PBYI shares. Weiss Ratings downgraded shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Wall Street Zen downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Puma Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Hedge Funds Weigh In On Puma Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of PBYI. BNP Paribas Financial Markets increased its position in Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,290 shares in the last quarter. CWM LLC grew its stake in Puma Biotechnology by 214.1% during the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 6,450 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Puma Biotechnology in the fourth quarter worth $59,000. Cerity Partners LLC purchased a new position in shares of Puma Biotechnology in the 2nd quarter valued at $36,000. Finally, Caprock Group LLC acquired a new position in shares of Puma Biotechnology during the 3rd quarter valued at $59,000. 61.29% of the stock is owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.